Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439999 | 1.00 | DPYD (0.40) | DPYDGAA | |
| SCHEMBL7603326 | 0.84 | DPYD (0.39) | DPYDGAA | |
| SCHEMBL30361611 | 0.82 | DPYD (0.38) | DPYDGAA | |
| SCHEMBL28838402 | 0.81 | DPYD (0.40) | DPYDGAA | |
| SCHEMBL7602273 | 0.80 | GAA (0.42) | DPYDGAA | |
| SCHEMBL29822911 | 0.79 | DPYD (0.44) | DPYDGAA | |
| SCHEMBL786710 | 0.77 | ATAD2 (0.40) | DPYD | |
| SCHEMBL175877 | 0.77 | DPYD (0.52) | DPYDGAA | |
| SCHEMBL2320491 | 0.75 | ALDH1A1 (0.48) | DPYDGAA | |
| SCHEMBL2037916 | 0.74 | DPYD (0.46) | DPYDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1700 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250320496-A1 | MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-10-16 | — | — | US | claimed |
| EP-4627084-A1 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | Camp4 Therapeutics Corporation (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250290072-A1 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-09-18 | — | — | US | claimed |
| US-20250250575-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-08-07 | — | — | US | claimed |
| US-20250243488-A1 | METHODS OF MODULATING PROGRANULIN EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2025-07-31 | — | — | US | claimed |
| WO-2024119145-A9 | MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20100004317-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA | CITY OF HOPE (US) | 2010-01-07 | — | — | US | claimed |
| US-20100004435-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2010-01-07 | — | — | US | claimed |
| US-20100004318-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2010-01-07 | — | — | US | claimed |
| US-20100004436-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2010-01-07 | — | — | US | claimed |
| US-20090325181-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA | CITY OF HOPE (US) | 2009-12-31 | — | — | US | claimed |
| US-20090326046-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA | CITY OF HOPE (US) | 2009-12-31 | — | — | US | claimed |
| US-20090325286-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | claimed |
| US-20090325285-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA | CITY OF HOPE (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009131661-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF HEPATITIS C VIRUS (HCV) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2003012052-A2 | SPECIFIC INHIBITION OF GENE EXPRESSION BY SMALL DOUBLE STRANDED RNAS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-02-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320496-A1 | MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | ABCB11, SLC10A1, SREBF1 | DPYD 2772/4885GAA 2677/4885 |
| US-20250250575-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CPS1, CTPS1, CTPS2 | DPYD 1073/4885GAA 529/4885 |
| US-20250243488-A1 | METHODS OF MODULATING PROGRANULIN EXPRESSION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | GRN, SNRPE, UPF1 | DPYD 2827/4885GAA 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.